Pharmacokinetics of chlorproguanil in man after a single oral dose of Lapudrine. 1988

J R Veenendaal, and M D Edstein, and K H Rieckmann
Army Malaria Research Unit, Milpo, Ingleburn, Australia.

The pharmacokinetic parameters of chlorproguanil (Lapudrine) and its active metabolite, chlorcycloguanil, were determined in 6 healthy male volunteers after a single oral dose of 4 Lapudrine tables (80 mg). The mean maximum plasma chlorproguanil concentration was 36.7 +/- (SD) 7.9 ng/ml and was reached at 3.8 +/- 1.3 h. The chlorproguanil elimination half-life was 17.5 +/- 6.7 h and its plasma clearance was 1.28 +/- 0.12 l/h/kg. The mean whole blood to plasma ratio was 3.1 at 4 h after dosing. Chlorcycloguanil could not be quantified in plasma and whole blood at the detection limit of 10 ng/ml using a high-performance liquid chromatographic method. An excretion rate-time plot from urine data shows a rapid (t1/2 = 20 h) and a slow phase (t1/2 = 51 h) in the elimination of chlorcycloguanil. Our findings suggest that the current prophylactic regimen of chlorproguanil hydrochloride (20 mg weekly) may not be optimal in preventing infections with chloroquine-resistant falciparum malaria.

UI MeSH Term Description Entries
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D002727 Proguanil A biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent. Chlorguanid,Chloroguanide,Bigumal,Chloriguane,Chloroguanide Hydrochloride,Paludrin,Paludrine,Proguanil Hydrochloride,Hydrochloride, Chloroguanide,Hydrochloride, Proguanil
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014227 Triazines Heterocyclic rings containing three nitrogen atoms, commonly in 1,2,4 or 1,3,5 or 2,4,6 formats. Some are used as HERBICIDES. Triazine,Benzotriazines

Related Publications

J R Veenendaal, and M D Edstein, and K H Rieckmann
January 1975, The Journal of clinical endocrinology and metabolism,
J R Veenendaal, and M D Edstein, and K H Rieckmann
May 1982, British journal of clinical pharmacology,
J R Veenendaal, and M D Edstein, and K H Rieckmann
April 1992, British journal of clinical pharmacology,
J R Veenendaal, and M D Edstein, and K H Rieckmann
January 1987, Biopharmaceutics & drug disposition,
J R Veenendaal, and M D Edstein, and K H Rieckmann
January 1988, International journal of clinical pharmacology research,
J R Veenendaal, and M D Edstein, and K H Rieckmann
January 1972, Clinical pharmacology and therapeutics,
J R Veenendaal, and M D Edstein, and K H Rieckmann
June 1995, British journal of clinical pharmacology,
J R Veenendaal, and M D Edstein, and K H Rieckmann
April 1974, Journal of pharmacokinetics and biopharmaceutics,
J R Veenendaal, and M D Edstein, and K H Rieckmann
January 2002, Clinical pharmacokinetics,
J R Veenendaal, and M D Edstein, and K H Rieckmann
January 1991, European journal of clinical pharmacology,
Copied contents to your clipboard!